Emergency Use Authorization
Emergency Use Authorization (EUA) information, and list of all current EUAs
About Emergency Use Authorizations (EUAs)
The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.
Section 564 of the FD&C Act was amended by the Project Bioshield Act of 2004 and was further amended by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), the 21st Century Cures Act of 2016, and Public Law 115-92 of 2017.
Guidance
In January 2017, FDA finalized the guidance: Emergency Use Authorization of Medical Products and Related Authorities. For more information, please see the January 13, 2017 Federal Register notice.
In addition, in January 2014, FDA issued a question and answer document (PDF, 762K) to respond to questions raised by public health stakeholders about PAHPRA’s amendments to the EUA authority and establishment of new authorities related to the emergency use of MCMs during CBRN emergencies.
General Emergency Diagnostics Information
- Emergency Use Authorizations (current device EUAs)
- How to Submit a Pre-EUA for In vitro Diagnostics (IVDs) to FDA (for test manufacturers)
- Information for Laboratories Implementing IVD Tests Under EUA
Coronavirus Disease 2019 (COVID-19) EUA Information
- Coronavirus Disease (COVID-19) updates from FDA
- Overviews:
- Detailed Information for all COVID-19 EUAs, including authorizations and fact sheets
In Vitro Diagnostic Products
On February 4, 2020, the HHS Secretary determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. On the basis of this determination, the Secretary then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19. The EUAs subsequently issued by FDA are listed in the table below this blue box.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (February 4, 2020)
In continuing response to the COVID-19 pandemic, on March 24, 2020, and based on the February 4, 2020 HHS EUA determination, the HHS Secretary declared that circumstances exist justifying the authorization of emergency use of medical devices, including alternative products used as medical devices, due to shortages during the COVID-19 outbreak.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (March 24, 2020)
On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to development of in vitro diagnostic tests during this public health emergency. This guidance was updated on March 16, 2020, May 4, 2020, and May 11, 2020.
CDC has granted a right of reference to the performance data contained in CDC's EUA (FDA submission number EUA200001) to any entity seeking an FDA EUA for a COVID-19 diagnostic device.
Templates for these EUA submissions are available to help facilitate the preparation, submission, and authorization of an EUA.
If you need additional information, please refer to the FAQs on Diagnostic Testing for SARS-CoV-2.
The HHS Secretary issued a Declaration pursuant to section 319F-3 of the Public Health Service Act to provide liability immunity for activities related to medical countermeasures against COVID-19.
- Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19 (February 4, 2020)
Please note: a determination under section 319 of the Public Health Service Act that a public health emergency exists, such as the one issued on January 31, 2020, does not enable FDA to issue EUAs. A separate determination and declaration are needed under section 564 of the Federal Food, Drug and Cosmetic Act to enable FDA to issue EUAs, provided other statutory criteria are met.
| Date EUA First Issued | Entity | Diagnostic (Most Recent Letter of Authorization) in PDF | Technology | Authorized Setting(s)1 | Authorization Labeling2 in PDF | Amendments and Other Documents in PDF | Federal Register Notice for EUA |
|---|---|---|---|---|---|---|---|
| 04/23/2020 | SD Biosensor, Inc. | STANDARD M nCoV Real-Time Detection Kit (129KB) | Molecular | H | HCP (136KB) Patients (124KB) IFU (548KB) |
|
|
| 02/04/2020 | CDC | CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel (286KB) (Reiussed 03/15/2020) | Molecular | H | HCP (144KB) Patients (121KB) IFU (1.7MB) |
|
|
| 02/29/2020 | Wadsworth Center, NYSDOH | New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (312KB) (Reissued 03/10/2020) | Molecular | H | HCP (140KB) Patients (117KB) IFU (314KB) |
|
|
| 03/12/2020 | Roche Molecular Systems, Inc. (RMS) | cobas SARS-CoV-2 (111KB) | Molecular | H, M | HCP (250KB) Patients (193KB) IFU (1.58MB) |
|
|
| 03/13/2020 | Thermo Fisher Scientific, Inc. | TaqPath COVID-19 Combo Kit (105KB) | Molecular | H | HCP (135KB) Patients (122KB) IFU (629KB) |
|
|
| 03/16/2020 | Hologic, Inc. | Panther Fusion SARS-CoV-2 Assay (290KB) | Molecular | H | HCP (135KB) Patients (124KB) IFU (423KB) |
|
|
| 03/16/2020 | Laboratory Corporation of America | COVID-19 RT-PCR Test (296KB) (reissued April 20, 2020) | Molecular | H | HCP (138KB) Patients (122KB) EUA Summary (426KB) IFU - Home Collection (2.24MB) |
|
|
| 03/17/2020 | Quidel Corp. | Lyra SARS-CoV-2 Assay (294KB) | Molecular | H | HCP (133KB) Patients (121KB) IFU (479KB) |
|
|
| 03/17/2020 | Quest Diagnostics Infectious Disease, Inc. |
Quest SARS-CoV-2 rRT-PCR (297KB) (reissued May 27, 2020) |
Molecular | H | HCP (138KB) Patients (126KB) IFU (257KB) IFU (Home Collect) (627KB) |
|
|
| 03/18/2020 | Abbott Molecular | Abbott RealTime SARS-CoV-2 assay (324KB) | Molecular | H | HCP (155KB) Patients (144KB) IFU (351KB) |
|
|
| 03/19/2020 | DiaSorin Molecular LLC | Simplexa COVID-19 Direct (103KB) | Molecular | H, M | HCP (135KB) Patients (122KB) IFU (291KB) |
|
|
| 03/19/2020 | GenMark Diagnostics, Inc. | ePlex SARS-CoV-2 Test (126KB) | Molecular | H, M | HCP (143KB) Patients (128KB) IFU (257KB) |
|
|
| 03/20/2020 | Primerdesign Ltd | Primerdesign Ltd COVID-19 genesig Real-Time PCR assay (132KB) | Molecular | H | HCP (137KB) Patients (125KB) IFU (1,013KB) |
|
|
| 03/20/2020 | Cepheid | Xpert Xpress SARS-CoV-2 test (140 KB) | Molecular | H, M, W | HCP (135KB) Patients (121KB) IFU - Laboratories (310KB) IFU - Point of Care (1.47MB) |
|
|
| 03/23/2020 | BioFire Defense, LLC | BioFire COVID-19 Test (317 KB) | Molecular | H, M | HCP (135KB) Patients (123KB) IFU (3.44MB) |
|
|
| 03/23/2020 | Mesa Biotech Inc. | Accula SARS-Cov-2 Test (322 KB) | Molecular | H, M, W | HCP (135KB) Patients (123KB) IFU (2.29MB) |
|
|
| 03/24/2020 | PerkinElmer, Inc. | PerkinElmer New Coronavirus Nucleic Acid Detection Kit (319 KB) | Molecular | H | HCP (133KB) Patients (121KB) IFU (374KB) |
|
|
| 03/25/2020 | Avellino Lab USA, Inc. | AvellinoCoV2 test (284KB) | Molecular | H | HCP (139KB) Patients (120KB) EUA Summary (135KB) |
|
|
| 03/26/2020 | BGI Genomics Co. Ltd | Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 (131KB) | Molecular | H | HCP (163KB) Patients (151KB) IFU (1.07MB) |
|
|
| 03/27/2020 | Abbott Diagnostics Scarborough, Inc. | ID NOW COVID-19 (356KB) | Molecular | H, M, W | HCP (137KB) Patients (124KB) IFU (2.95MB) |
|
|
| 03/27/2020 | Luminex Molecular Diagnostics, Inc. | NxTAG CoV Extended Panel Assay (318KB) | Molecular | H | HCP (136KB) Patients (123KB) IFU (768KB) |
|
|
| 03/30/2020 | NeuMoDx Molecular, Inc. | NeuMoDx SARS-CoV-2 Assay (127KB) |
Molecular | H, M | HCP (135KB) Patients (124KB) IFU (441KB) |
|
|
| 03/30/2020 | QIAGEN GmbH | QIAstat-Dx Respiratory SARS-CoV-2 Panel (128KB) | Molecular | H, M | HCP (140KB) Patients (124KB) IFU (1.81MB) |
|
|
| 04/01/2020 | Cellex Inc. | qSARS-CoV-2 IgG/IgM Rapid Test (328KB) | Serology IgM and IgG | H, M | HCP (139KB) Patients (126KB) IFU (325KB) |
|
|
| 04/01/2020 | Ipsum Diagnostics, LLC | COV-19 IDx assay (288KB) | Molecular | H | HCP (133KB) Patients (121KB) EUA Summary (130KB) |
|
|
| 04/02/2020 | Becton, Dickinson & Company (BD) | BioGX SARS-CoV-2 Reagents for BD MAX System (154KB) | Molecular | H, M | HCP (143KB) Patients (131KB) IFU (1.68MB) |
|
|
| 04/03/2020 | Luminex Corporation | ARIES SARS-CoV-2 Assay (125KB) | Molecular | H, M | HCP (138KB) Patients (124KB) IFU (5.22MB) |
|
|
| 04/03/2020 | ScienCell Research Laboratories | ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit (319KB) | Molecular | H | HCP (141KB) Patients (129KB) IFU (376KB) |
|
|
| 04/03/2020 | Co-Diagnostics, Inc. | Logix Smart Coronavirus Disease 2019 (COVID-19) Kit (317KB) | Molecular | H | HCP (135KB) Patients (123KB) IFU (476KB) |
|
|
| 04/06/2020 | Gnomegen LLC | Gnomegen COVID-19 RT-Digital PCR Detection Kit (320KB) | Molecular | H | HCP (135KB) Patients (123KB) IFU (227KB) |
|
|
| 04/07/2020 | InBios International, Inc. | Smart Detect SARS-CoV-2 rRT-PCR Kit (128KB) | Molecular | H | HCP (158KB) Patients (144KB) IFU (252KB) |
|
|
| 04/08/2020 | Becton, Dickinson & Company | BD SARS-CoV-2Reagents for BD MAX System (212KB) | Molecular | H, M | HCP (160KB) Patients (139KB) IFU (1.5MB) |
|
|
| 04/08/2020 | DiaCarta, Inc. | QuantiVirus SARS-CoV-2 Test kit (319KB) | Molecular | H | HCP (135KB) Patients (123KB) IFU (687KB) |
|
|
| 04/10/2020 | Atila BioSystems, Inc. | iAMP COVID-19 Detection Kit (124KB) | Molecular | H | HCP (137KB) Patients (124KB) IFU (434KB) |
|
|
| 04/14/2020 | Ortho Clinical Diagnostics, Inc. | VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack (379KB) | Serology Total Antibody | H, M | HCP (232KB) Recipients (187KB) IFU (370KB) |
|
|
| 04/14/2020 | Chembio Diagnostic System, Inc. | DPP COVID-19 IgM/IgG System (369KB) | Serology IgM and IgG | H, M | HCP (236KB) Patients (213KB) IFU (1.06MB) |
|
|
| 04/15/2020 | Maccura Biotechnology (USA) LLC | SARS-CoV-2 Fluorescent PCR Kit (154KB) | Molecular | H | HCP (138KB) Patients (139KB) IFU (1.25MB) |
|
|
| 04/15/2020 | Mount Sinai Laboratory | COVID-19 ELISA IgG Antibody Test (339KB) | Serology IgG | H | HCP (334KB) Patients (256KB) EUA Summary (301KB) |
|
|
| 04/16/2020 | GenoSensor, LLC | GS COVID-19 RT-PCR KIT (317KB) | Molecular | H | HCP (133KB) Patients (121KB) IFU (408KB) |
|
|
| 04/16/2020 | KorvaLabs Inc. | Curative-Korva SARS-Cov-2 Assay (280KB) | Molecular | H | HCP (135KB) Patients (123KB) EUA Summary (273KB) |
|
|
| 04/17/2020 | Fosun Pharma USA Inc. | Fosun COVID-19 RT-PCR Detection Kit (317KB) | Molecular | H | HCP (249KB) Patients (190KB) IFU (391KB) |
|
|
| 04/18/2020 | OSANG Healthcare | GeneFinder COVID-19 Plus RealAmp Kit (320KB) | Molecular | H | HCP (137KB) Patients (125KB) IFU (494KB) |
|
|
| 04/20/2020 | Trax Management Services Inc. | PhoenixDx 2019-CoV (134KB) | Molecular | H |
|
||
| 04/21/2020 | Seegene, Inc. | Allplex 2019-nCoV Assay (124KB) | Molecular | H | HCP (135KB) Patients (121KB) IFU (2.04MB) |
|
|
| 04/22/2020 | altona Diagnostics GmbH | RealStar SARS-CoV02 RT-PCR Kits U.S. (130KB) | Molecular | H | HCP (138KB) Patients (126KB) IFU (566KB) |
|
|
| 04/24/2020 | DiaSorin Inc. | LIAISON SARS-CoV-2 S1/S2 IgG (368KB) | Serology IgG only | H, M | HCP (139KB) Recipients (124KB) IFU (306KB) |
|
|
| 04/24/2020 | Ortho-Clinical Diagnostics, Inc. | VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack (370KB) | Serology IgG only | H, M | HCP (150KB) Recipients (135KB) IFU (325KB) |
|
|
| 04/24/2020 | Autobio Diagnostics Co. Ltd. | Anti-SARS-CoV-2 Rapid Test (329KB) | Serology IgM and IgG | H, M | HCP (83KB) Recipients (92KB) IFU (350KB) |
|
|
| 04/27/2020 | SEASUN BIOMATERIALS | U-TOP COVID-19 Detection Kit (129KB) | Molecular | H | HCP (143KB) Patients (125KB) IFU (1.04MB) |
|
|
| 04/26/2020 | Abbott Laboratories Inc. | SARS-CoV-2 IgG assay (367KB) | Serology IgG only | H, M | HCP (112KB) Recipients (98KB) IFU-ARCHITECT (566KB) IFU-Alinityi (2.51MB) |
|
|
| 04/29/2020 | LabGenomics Co., Ltd. | LabGun COVID-19 RT-PCR Kit (134KB) | Molecular | H | HCP (109KB) Patients (98KB) IFU (1.39MB) |
|
|
| 04/29/2020 | Rheonix, Inc. | Rheonix COVID-19 MDx Assay (133KB) | Molecular | H | HCP (107KB) Patients (97KB) IFU (3.47MB) |
|
|
| 04/29/2020 | Bio-Rad Laboratories | Platelia SARS-CoV-2 Total Ab assay (141KB) | Serology Total Antibody | H | HCP (110KB) Recipients (96KB) IFU (293KB) |
|
|
| 04/30/2020 | Wadsworth Center, New York State Department of Health | New York SARS-CoV Microsphere Immunoassay for Antibody Detection (115KB) | Serology Total Antibody | H | HCP (158KB) Recipients (140KB) EUA Summary (92KB) |
|
|
| 05/01/2020 | Bio-Rad Laboratories, Inc. | Bio-Rad SARS-CoV-2 ddPCR Test (319KB) | Molecular | H | HCP (137KB) Patients (125KB) IFU (1.54MB) |
|
|
| 05/01/2020 | BioFire Diagnostics, LLC | BioFire Respiratory Panel 2.1 (RP2.1) (400KB) | Molecular | H, M | HCP (139KB) Patients (126KB) IFU (1.24MB) |
|
|
| 05/02/2020 | Roche Diagnostics | Elecsys Anti-SARS-CoV-2 (302KB) | Serology Antibody | H, M | HCP (145KB) Recipients (125KB) IFU (136KB) |
|
|
| 05/04/2020 | EUROIMMUN US Inc. | Anti-SARS-CoV-2 ELISA (IgG) (333KB) | Serology IgG | H | HCP (42KB) Recipients (51KB) IFU (241KB) |
|
|
| 05/04/2020 | Sansure BioTech Inc. | Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing) (360KB) | Molecular | H | HCP (212KB) Patients (171KB) IFU (988KB) |
|
|
| 05/05/2020 | Fast Track Diagnostics Luxembourg S.á.r.l. (a Siemens Healthineers Company) | FTD SARS-CoV-2 (300KB) | Molecular | H | HCP (141KB) Patients (129KB) IFU (944KB) |
|
|
| 05/06/2020 | OPTI Medical Systems, Inc. | OPTI SARS-CoV-2 RT PCR Test (396KB) | Molecular | H | HCP (312KB) Patients (231KB) IFU (1.04MB) |
|
|
| 05/06/2020 | Sherlock BioSciences, Inc. | Sherlock CRISPR SARS-CoV-2 Kit (397KB) | Molecular | H | HCP (250KB) Patients (190KB) IFU (1.15MB) |
|
|
| 05/06/2020 | BioMérieux SA | SARS-COV-2 R-GENE (422KB) | Molecular | H | HCP (254KB) Patients (191KB) IFU (1.16MB) |
|
|
| 05/07/2020 | Zymo Research Corporation | Quick SARS-CoV-2rRT-PCR Kit (396KB) | Molecular | H | HCP (289KB) Patients (245KB) IFU (630KB) |
|
|
| 05/07/2020 | Rutgers Clinical Genomics Laboratory at RUCDR Infinite Biologics - Rutgers University | Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2-Assay (381KB) | Molecular | H | HCP (253KB) Patients (193KB) IFU (551KB) EUA Summary (252KB) |
|
|
| 05/08/2020 | Quidel Corporation | Sofia 2 SARS Antigen FIA (138KB) | Antigen | H, M, W | HCP (110KB) Patients (100KB) IFU (1.3MB) |
|
|
| 05/08/2020 | Gnomegen LLC | Gnomegen COVID-19-RT-qPCR Detection Kit (314KB) | Molecular | H | HCP (135KB) Patients (123KB) IFU (1.36MB) |
|
|
| 05/11/2020 | 1drop Inc. | 1copy COVID-19 qPCR Multi Kit (395KB) | Molecular | H | HCP (347KB) Patients (264KB) IFU (2.61MB) |
|
|
| 05/11/2020 | Abbott Molecular Inc. | Alinity m SARS-CoV-2 assay (394KB) | Molecular | H | HCP (248KB) Patients (189KB) IFU (960KB) |
|
|
| 05/13/2020 | Applied DNA Sciences, Inc. | Linea COVID-19 Assay Kit (393KB) | Molecular | H | HCP (252KB) Patients (191KB) IFU (210KB) |
|
|
| 05/14/2020 | Hologic, Inc. | Aptima SARS-CoV-2 assay (131KB) | Molecular | H | HCP (108KB) Patients (97KB) IFU (403KB) |
|
|
| 05/14/2020 | GeneMatrix, Inc. | NeoPlex COVID-19 Detection Kit (135KB) | Molecular | H | HCP (109KB) Patients (98KB) IFU (847KB) |
|
|
| 05/15/2020 | Everlywell, Inc. | Everlywell COVID-19 Test Home Collection Kit (307KB) | Home Collection Kit | N/A | IFU (624KB) EUA Summary (351KB) |
|
|
| 05/15/2020 | Fulgent Therapeutics, LLC | Fulgent COVID-19 by RT-PCR Test (288KB) | Molecular | H | HCP (138KB) Patients (126KB) EUA Summary (385KB) |
|
|
| 05/15/2020 | Assurance Scientific Laboratories | Assurance SARS-CoV-2 Panel (287KB) | Molecular | H | HCP (137KB) Patients (125KB) EUA Summary (420KB) |
|
|
| 05/18/2020 | Quidel Corporation | Lyra Direct SARS-CoV-2 Assay (396KB) | Molecular | H | HCP (250KB) Patients (190KB) IFU (596KB) |
|
|
| 05/21/2020 | BioCore Co., Ltd. | BioCore 2019-nCoV Real Time PCR Kit (415KB) | Molecular | H | HCP (252KB) Patients (190KB) IFU (1.87MB) |
|
|
| 05/21/2020 | SolGent Co., Ltd. | DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit (393KB) | Molecular | H | HCP (250KB) Patients (209KB) IFU (2.06MB) |
|
|
| 05/21/2020 | Seasun Biomaterials, Inc. | AQ-TOP COVID-19 Rapid Detection Kit (395KB) | Molecular | H | HCP (254KB) Patients (192KB) IFU (1.02MB) |
|
|
| 05/21/2020 | P23 Labs, LLC. | P23 Labs TaqPath SARS-CoV-2 Assay (372KB) | Molecular | H | HCP (260KB) Patients (190KB) IFU- Home Collect (964KB) EUA Summary (629KB) |
|
|
| 05/22/2020 | dba SpectronRx | Hymon SARS-CoV-2 Test Kit (133KB) | Molecular | H | HCP (109KB) Patients (97KB) IFU (232KB) |
|
|
| 05/28/2020 | PrivaPath Diagnostics, Inc. | LetsGetChecked Coronavirus (COVID-19) Test (295KB) | Molecular | H | HCP (142KB) Patients (129KB) IFU- Home Collect (459KB) EUA Summary (92KB) |
|
|
1 Settings for use include the following:
- H - Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.
- M - Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate complexity tests.
- W - Patient care settings operating under a CLIA Certificate of Waiver.
2 Authorization Documents include the Healthcare Provider (HCP) and Patient Fact Sheets and either the Manufacture Instructions/Package Insert (abbreviated to IFU) or the EUA Summary.
High Complexity Molecular-Based Laboratory Developed Tests
On March 31, 2020, the FDA concluded based on the totality of scientific evidence available that molecular-based laboratory developed tests (LDTs) that are authorized for use by the singular developing laboratory are appropriate to protect the public health or safety (as described under the Scope of Authorization (Section II)) under section 564 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 360bbb-3). Under this EUA, authorized tests are authorized for use in the single laboratory that developed the authorized test and that is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a to perform high complexity tests.
- EUA Letter of Authorization - Laboratories Who Have Developed a Molecular-Based Test (LDTs) for Coronavirus Disease 2019 (COVID-19) (144KB)
- Fact Sheet for Healthcare Providers (134KB)
- Fact Sheet for Patients (123KB)
- See the table below for a current list of included laboratories and their LDTs
| Date of EUA Issuance | Laboratory | Letter Granting Inclusion Under EUA in PDF | EUA Summary in PDF |
|---|---|---|---|
| 03/31/2020 | Yale New Haven Hospital, Clinical Virology Laboratory | SARS-CoV-2 PCR test (72KB) | EUA Summary (121KB) |
| 04/02/2020 | Infectious Disease Diagnostics Laboratory - Children's Hospital of Philadelphia | SARS-CoV-2 RT-PCR test (121KB) | EUA Summary (333 KB) |
| 04/02/2020 | Diagnostic Molecular Laboratory - Northwestern Medicine | SARS-Cov-2 Assay (152KB) | EUA Summary (272KB) |
| 04/03/2020 | Massachusetts General Hospital | MGH COVID-19 qPCR assay (68KB) | EUA Summary (122KB) |
| 04/06/2020 | Viracor Eurofins Clinical Diagnostics | Viracor SARS-CoV-2 assay (120KB) | EUA Summary (65KB) |
| 04/08/2020 | Stanford Health Care Clinical Virology Laboratory | Stanford SARS-CoV-2 assay (79KB) | EUA Summary (180KB) |
| 04/10/2020 | Specialty Diagnostic (SDI) Laboratories | SDI SARS-CoV-2 AssayLetter Granting Inclusion (68KB) | EUA Summary (160KB) |
| 04/10/2020 | Orig3n, Inc. | Orig3n 2019 Novel Coronavirus (COVID-19) Test (68KB) | EUA Summary (140KB) |
| 04/10/2020 | University of North Carolina Medical Center | UNC Health SARS-CoV-2 real-time RT-PCR test (120KB) | EUA Summary (611KB) |
| 04/13/2020 | Pathology/Laboratory Medicine Lab of Baptist Hospital Miami | COVID-19 RT-PCR Test (121KB) | EUA Summary (351KB) |
| 04/13/2020 | Integrity Laboratories | SARS-CoV-2 Assay (121KB) | EUA Summary (409KB) |
| 04/14/2020 | Exact Sciences Laboratories | SARS-CoV-2 Test (120KB) | EUA Summary (513KB) |
| 04/14/2020 | Infectious Diseases Diagnostics Laboratory (IDDL), Boston Children's Hospital | Childrens-Altona-SARS-CoV-2 Assay (145KB) | EUA Summary (346KB) |
| 04/15/2020 | CirrusDx Laboratories | CirrusDx SARS-CoV-2 Assay (164KB) | EUA Summary (411KB) |
| 04/15/2020 | Hackensack University Medical Center (HUMC) Molecular Pathology Laboratory | CDI Enhanced COVID-19 Test (218KB) | EUA Summary (355KB) |
| 04/20/2020 | Mayo Clinic Laboratories, Rochester, MN | SARS-CoV-2 Molecular Detection Assay (68KB) | EUA Summary (171KB) |
| 04/22/2020 | Diatherix Eurofins Laboratory | SARS-CoV-2 PCR Test (68KB) | EUA Summary (151KB) |
| 04/23/2020 | Southwest Regional PCR Laboratory LLC. dba MicroGen DX | COVID-19 Key (121KB) | EUA Summary (419KB) |
| 04/24/2020 | AIT Laboratories | SARS-CoV-2 Assay (120KB) | EUA Summary (423KB) |
| 04/24/2020 | Ultimate Dx Laboratory | UDX SARS-CoV-2 Molecular Assay (120KB) | EUA Summary (554KB) |
| 04/27/2020 | Nationwide Children’s Hospital | SARS-CoV-2 Assay (67KB) | EUA Summary (185KB) |
| 04/30/2020 | Altru Diagnostics, Inc. | Altru Dx SARS-CoV-2 RT-PCR assay (78KB) | EUA Summary (143KB) |
| 04/28/2020 | Biocerna | SARS-CoV-2 Test (218KB) | EUA Summary (307KB) |
| 05/03/2020 | UTMG Pathology Laboratory | UTHSC/UCH SARS-CoV-2-RT-PCR Assay (218KB) | EUA Summary (269KB) |
| 05/07/2020 | Biocollections Worldwide, Inc. | Biocollections Worldwide SARS-Co-V-2 Assay (120KB) | EUA Summary (365KB) |
| 05/12/2020 | Columbia University Laboratory of Personalized Genomic Medicine | Triplex CII-CoV-1 rRT-PCR Test (214KB) | EUA Summary (768KB) |
| 05/13/2020 | One Health Laboratories, LLC | SARS-CoV-2 Real-Time RT-PCR-Test (222KB) | EUA Summary (394KB |
| 05/13/2020 | Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine | SARS-CoV-2-Assay (223KB) | EUA Summary (424KB) |
| 05/18/2020 | Color Genomics, Inc. | Color SARS CoV-2 Diagnostic Assay (223KB) | EUA Summary (630KB) |
| 05/22/2020 | Exact Sciences Laboratories | Exact Sciences SARS-CoV-2 (N gene detection) Test (120KB) | EUA Summary (191KB) |
| 05/22/2020 | Express Gene LLC (dba Molecular Diagnostics Laboratory) | Express Gene 2019-nCoV RT-PCR Diagnostic Panel (120KB) | EUA Summary (143KB) |
| 05/22/2020 | Avera Institute for Human Genetics | Avera Institute for Human Genetics SARS-CoV-2 Assay (120KB) | EUA Summary (143KB) |
SARS-CoV-2 Antibody Tests
On April 28, 2020, FDA issued an Emergency Use Authorization for SARS-CoV-2 Antibody Tests (Lateral flow or Enzyme-linked immunosorbent assay (ELISA) tests) that have been evaluated in an independent validation study performed at the National Institutes of Health’s (NIH) National Cancer Institute (NCI), or by another government agency designated by FDA, and are confirmed by FDA to meet the criteria set forth in the Scope of Authorization (Section II) in the Letter of Authorization under section 564 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 360bbb-3). Under this EUA, authorized devices are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, by detecting antibodies (IgG, or IgG and IgM, or total), as specified in each authorized device’s instructions for use, to SARS-CoV-2 in human plasma and/or serum.
Emergency use of the authorized devices is limited to the authorized laboratories. Authorized Laboratories are laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform moderate or high complexity tests. Authorized devices will be added to Appendix A (below) upon submission of the information set forth in the Scope of Authorization (Section II) and after confirmation that the applicable performance and labeling criteria set forth in the Scope of Authorization (Section II) have been met.
- Letter of Authorization – Serology IVD Umbrella (PDF, 83KB)
- Fact Sheet for Healthcare Providers (PDF, 79KB)
- Fact Sheet for Recipients (PDF, 102KB)
- Appendix A Table (PDF, 72KB)
Personal Protective Equipment and Related Devices
For information on the applicable HHS Secretary determination and declaration supporting a particular EUA in the table below, as well as a link to any applicable PREP Act declaration, please use the expansion buttons on the left hand side of the table.
For additional information, please see Recent Final Medical Device Guidance Documents and Coronavirus (COVID-19) Update: FDA takes action to increase U.S. supplies through instructions for PPE and device manufacturers.
Please also see the Non-NIOSH Approved Respirator FAQ for additional information.
Ventilators and Other Medical Devices
In continuing response to the COVID-19 pandemic, on March 24, 2020, and based on the February 4, 2020 HHS EUA determination, the HHS Secretary declared that circumstances exist justifying the authorization of emergency use of medical devices, including alternative products used as medical devices, due to shortages during the COVID-19 outbreak. The EUAs FDA subsequently authorized based on this determination and declaration are listed in the table below this blue box.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (March 24, 2020)
The HHS Secretary issued a Declaration pursuant to section 319F-3 of the Public Health Service Act to provide liability immunity for activities related to medical countermeasures against COVID-19.
- Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19 (February 4, 2020)
Templates for these EUA submissions are available to help facilitate the preparation, submission, and authorization of an EUA.
1 The multiBic/multiPlus Solutions include multiBic dialysate and replacement fluid and multiPlus dialysate. The multiFiltrate PRO System, multiBic dialysate and the multiPlus dialysate solutions are regulated as devices by CDRH. The multiBic replacement fluid is regulated as a drug by CDER.
Drug Products
On February 4, 2020, the HHS Secretary determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. On the basis of this determination, the Secretary then declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C Act, effective March 27, 2020. The EUAs subsequently issued by FDA are listed in the table below this blue box.
1 The virus that causes COVID-19 has led to an increased number of patients requiring critical care, such as with severe respiratory illness. As a result, there is a shortage of adequate, FDA-approved drugs used for their treatment, such as propofol for sedation of mechanically ventilated patients.
2 In the circumstances of this public health emergency, it would not be feasible to require healthcare providers to seek to limit Fresenius Propoven 2% Emulsion only to be used for patients with suspected or confirmed COVID-19; therefore, this authorization does not limit use to such patients.
3 The multiBic/multiPlus Solutions include multiBic dialysate and replacement fluid and multiPlus dialysate. The multiBic replacement fluid is regulated as a drug by CDER. The multiFiltrate PRO System, multiBic dialysate and the multiPlus dialysate solutions are regulated as devices by CDRH.
Other Current EUAs
The tables below provide information on current EUAs:
- Anthrax EUAs
- Ebola Virus EUA Information
- Enterovirus D68 (EV-D68) EUA Information
- Freeze Dried Plasma Information
- H7N9 Influenza EUA Information
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV) EUA Information
- Nerve Agent EUA Information
- Zika Virus EUA Information
Information about EUAs that are no longer in effect is available on our EUA archive page.
The 2016 FDA Doxycycline Emergency Dispensing Order and CDC Doxycycline Emergency Use Instructions (EUI) together replace the need for the doxycycline mass dispensing EUA (issued on July 21, 2011). Therefore, the doxycycline emergency dispensing order and EUI should be used by stakeholders for anthrax preparedness and response instead of the mass dispensing EUA.
The July 21, 2011, doxycycline mass dispensing EUA, and the October 14, 2011, National Postal Model anthrax EUA will be terminated by FDA, and notice of such termination will be published in the Federal Register. For additional information, see Emergency Use Authorization--Archived Information.
Ebola preparedness and response updates from FDA (all agency activities)
For more information about the diagnostics below, also see Emergency Use Authorizations (current device EUAs).
Ebola Diagnostic Tests with De Novo, 510(k) or PMA
- OraQuickEbola Rapid Antigen Test - On October 10, 2019, FDA allowed marketing (PDF, 255 KB) of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola (cadaveric oral fluid). The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for Ebola virus disease (EVD). The test provides a rapid, presumptive diagnosis that must be confirmed. Also see the FDA news release: FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens
The OraQuick Ebola Test was reviewed under the De Novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this marketing authorization, the FDA is establishing criteria, called special controls, that determine the requirements for demonstrating accuracy, reliability and effectiveness of tests intended to identify Ebola virus antigens. These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for tests of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
EZ1 Real-time RT-PCR Assay |
August 5, 2014 (initial issuance) October 10, 2014 (reissuance)
|
Authorization (PDF, 61 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
CDC Ebola Virus NP Real-time RT-PCR Assay |
October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
|
Authorization (PDF, 282 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
CDC Ebola Virus VP40 Real-time RT-PCR Assay |
October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
|
Authorization (PDF, 285 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
FilmArray NGDS BT-E Assay |
October 25, 2014 (initial issuance) March 2, 2015 (reissuance)
|
Authorization (PDF, 326 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
FilmArray Biothreat-E test |
October 25, 2014 November 12, 2019 (amended) |
Authorization (PDF, 73 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
RealStar Ebolavirus RT-PCR Kit 1.0 |
November 10, 2014 (initial issuance) November 26, 2014 (reissuance)
|
Authorization (PDF, 263 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
LightMix Ebola Zaire rRT-PCR Test |
December 23, 2014 |
Authorization (PDF, 2.2 MB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
Xpert Ebola Assay |
March 23, 2015 |
Authorization (PDF, 240 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
Idylla Ebola Virus Triage Test (Biocartis NV) |
May 26, 2016 |
Authorization (PDF, 321 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
|
|
|
DPP Ebola Antigen System (Chembio Diagnostic Systems, Inc.) |
November 9, 2018 April 2, 2019 (amended) |
Authorization (PDF, 103 KB) Letter Granting EUA Amendment(s) (PDF, 87 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
For more information about the diagnostics below, also see Emergency Use Authorizations (current device EUAs).
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Enterovirus D68 2014 Real-time RT-PCR Assay (EV-D68 2014 rRT-PCR) |
May 12, 2015 |
Authorization (PDF, 229 KB) |
|
Determination and Declaration Regarding Emergency Use of New In Vitro Diagnostics for Detection of Enterovirus D68 (February 6, 2015) |
Also see FDA News Release: FDA takes action to support American military personnel by granting an authorization for freeze-dried plasma product to enable broader access while the agency works toward approval of the product (July 10, 2018)
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
Pathogen-Reduced Leukocyte-Depleted Freeze Dried Plasma (Centre de Transfusion Sanguine des Armées)
|
July 9, 2018 (initial issuance) May 8, 2020 (amendment) |
Authorization (PDF, 203 KB) Letter granting EUA amendments (PDF, 60 KB) |
|
Determination by DoD (June 7, 2018) Declaration Regarding Emergency Use of Treatment for Hemorrhage or Coagulopathy During an Emergency Involving Agents of Military Combat (July 9, 2018) |
For more information about the diagnostics below, also see Emergency Use Authorizations (current device EUAs).
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheet and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-Influenza A/H7 (Eurasian Lineage) Assay |
April 22, 2013 (initial issuance)
March 27, 2018 (reissuance) |
Authorization (PDF, 301 KB), re-issued March 27, 2018
|
|
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
|
|
Quidel Lyra Influenza A Subtype H7N9 Assay |
February 14, 2014 |
Authorization (PDF, 57 KB) |
|
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
|
|
A/H7N9 Influenza Rapid Test |
April 25, 2014 |
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
For more information about the diagnostics below, also see Emergency Use Authorizations (current device EUAs).
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Novel Coronavirus 2012 Real-time RT-PCR Assay |
June 5, 2013 (initial issuance) June 10, 2014 (reissuance)
|
Authorization (PDF, 2.2 MB) |
|
|
||
|
RealStar MERS-CoV RT-PCR Kit U.S. |
July 17, 2015 February 12, 2016 (reissuance)
|
Authorization (PDF, 238 KB) |
|
On July 9, 2018, FDA approved (PDF, 49 KB) the 2 mg Atropine Auto-Injector manufactured by Rafa Laboratories, Ltd., for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides in adults and pediatric patients weighing over 90 lbs [41 kg] (generally over 10 years of age). For more information about the approved 2 mg Rafa Atropine Auto-Injector, see the product label (PDF, 482 KB). The EUA detailed in the table below is still in effect.
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
Atropine Auto-Injector (Rafa Laboratories Ltd.) |
April 11, 2017 (initial issuance) May 23, 2017 (amended) January 24, 2018 (amended) March 6, 2018 (amended) May 15, 2018 (amended) |
Letter of Authorization (PDF, 514 KB) Letter granting EUA amendment(s) (PDF, 28 KB) 2nd letter granting EUA amendment(s) (PDF, 33 KB) 3rd letter granting EUA amendment(s) (PDF, 85 KB) 4th letter granting EUA amendment(s) (PDF, 42 KB) |
|
Determination and Declaration Regarding Nerve Agent or Certain Insecticide (Organophosphorus and/or Carbamate) Poisoning (April 11, 2017) |
Nerve Agents and Certain Insecticides (Organophosphorus and/or Carbamate) Countermeasures (April 11, 2017) |
Zika virus response updates from FDA
Zika virus diagnostic development information
For more information about the diagnostics below, also see Emergency Use Authorizations (current device EUAs).
Draft EUA review templates for Zika are available by email request to: CDRH-ZIKA-Templates@fda.hhs.gov
Laboratory personnel using Zika diagnostic assays under EUA are encouraged to report performance concerns directly to FDA at CDRH-EUA-Reporting@fda.hhs.gov, in addition to reporting concerns to the manufacturer.
Zika Diagnostic Tests with De Novo, 510(k), or PMA
- ZIKV Detect 2.0 IgM Capture ELISA - On May 23, 2019, FDA authorized marketing (PDF, 175 KB) of the ZIKV Detect 2.0 IgM Capture ELISA to detect Zika virus immunoglobulin (IgM) antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies—including the ZIKV Detect 2.0 IgM Capture ELISA—had been authorized only for emergency use under the FDA’s EUA authority. Also see the FDA news release: FDA authorizes marketing of first diagnostic test for detecting Zika virus antibodies
- ADVIA Centaur Zika test – On July 17, 2019, FDA cleared the ADVIA Centaur Zika test. This is the second Zika diagnostic test FDA has allowed to be marketed in the U.S. for detecting Zika virus IgM antibodies. Previously, the test had been authorized only for emergency use under FDA’s EUA authority.
- LIAISON XL Zika Capture IgM Assay II – On October 28, 2019, FDA cleared the LIAISON XL Zika Capture IgM Assay II for detecting Zika virus IgM antibodies. Previously, the test had been authorized only for emergency use under FDA’s EUA authority.
| Medical Product | Date of EUA Issuance | Letters | Federal Register Notice for EUA |
Fact Sheets and Manufacturer Instructions/Package Insert |
EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay |
February 26, 2016 (initial issuance) June 29, 2016 (amended) November 15, 2016 (amended) December 6, 2016 (amended) May 3, 2017 (amended) July 31, 2017 (amended) April 16, 2018 (amended) September 26, 2018 (amended) |
Letter granting EUA amendment(s) (PDF, 155 KB) Letter granting EUA amendment(s) (PDF, 123 KB) Letter granting EUA amendment(s) (PDF, 110 KB) Letter granting EUA amendment(s) (PDF, 113 KB) Letter granting EUA amendment(s) (PDF, 131 KB) Letter granting EUA amendment(s) (PDF, 131 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
CDC Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR) |
March 17, 2016 (initial issuance) September 21, 2016 (amended) January 12, 2017 (amended) February 28, 2017 (amended) April 6, 2017 (amended) |
Authorization (PDF, 82 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 126 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus RNA Qualitative Real-Time RT-PCR (Quest Diagnostics Infectious Disease, Inc.) |
April 28, 2016 (initial issuance) October 7, 2016 (reissuance) April 11, 2017 (amended) |
Authorization (PDF, 339 KB) Letter granting EUA amendment(s) (PDF, 126 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
RealStar Zika Virus RT-PCR Kit U.S. (altona Diagnostics GmbH) |
May 13, 2016 (initial issuance) October 31, 2016 (amended) March 6, 2017 (amended) |
Authorization (PDF, 342 KB) Letter Granting EUA Amendment(s) (PDF, 130 KB) Letter Granting EUA Amendment(s) (PDF, 130 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Aptima Zika Virus assay (Hologic, Inc.) |
June 17, 2016 (initial issuance) September 7, 2016 (amended) April 12, 2017 (amended) March 8, 2018 (amended)
|
Authorization (PDF, 305 KB) Letter granting EUA amendment(s) (PDF, 126 KB) Letter granting EUA amendment(s) (PDF, 124 KB) Letter granting EUA amendment(s) (PDF, 130 KB)
|
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus Real-time RT-PCR Test (Viracor Eurofins) |
July 19, 2016 (initial issuance) February 28, 2017 (amended) |
Authorization (PDF, 334 KB) Letter granting EUA amendment(s) (PDF, 124 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
VERSANT Zika RNA 1.0 Assay (kPCR) Kit (Siemens Healthcare Diagnostics Inc.) |
July 29, 2016 (initial issuance) December 19, 2016 (amended) |
Authorization (PDF, 78 KB) Letter granting EUA amendment(s) (PDF, 124 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Sentosa SA ZIKV RT-PCR Test (Vela Diagnostics USA, Inc.) |
September 23, 2016 |
Authorization (PDF, 355 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus Detection by RT-PCR Test (ARUP Laboratories) |
September 28, 2016 |
Authorization (PDF, 98 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Abbott RealTime ZIKA (Abbott Molecular Inc.) |
November 21, 2016 (initial issuance) January 6, 2017 (amended) |
Authorization (PDF, 84 KB) Letter granting EUA amendment(s) (PDF, 150 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika ELITe MGB Kit U.S. (ELITechGroup Inc. Molecular Diagnostics) |
December 9, 2016 |
Authorization (PDF, 312 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Gene-RADAR Zika Virus Test (Nanobiosym Diagnostics, Inc.) |
March 20, 2017 |
Authorization (PDF, 313 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
TaqPath Zika Virus Kit (Thermo Fisher Scientific) |
August 2, 2017 |
Authorization (PDF, 292 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016)
|
|
|
|
CII-ArboViroPlex rRT-PCR Assay (Columbia University) |
August 11, 2017 |
Authorization (PDF, 377 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
|
September 27, 2017 (initial issuance) February 6, 2018 (amended) August 3, 2018 (amended) |
Authorization (PDF, 424 KB) Letter granting EUA amendment(s) (PDF, 130 KB) Letter granting EUA amendment(s) (PDF, 129 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
Related Links
- Summary of Process for EUA Issuance
- Emergency Use Authorization--Archived Information
- Emergency Dispensing Orders
- Coronavirus Disease 2019 (COVID-19)
- 21st Century Cures Act: MCM-Related Cures Provisions
- Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA)
- Public Readiness and Emergency Preparedness (PREP) Act
- HHS Public Health Emergency EUA Authorization Declarations
- Ebola Preparedness and Response Updates from FDA
- Zika Virus Response Updates from FDA
- Emergency Use Authorizations (Medical Devices)
- Historical Information about Device Emergency Use Authorizations